Sarepta SRP-9001 Micro-dystrophin Gene Therapy Update and R&D Day
On October 4th, Sarepta Therapeutics announced the initiation, in partnership with Roche, of a pivotal study of SRP-9001-301 (rAAVrh74.MHCK7.micro-dystrophin) also known as EMBARK. Simultaneously, the company announced plans to host a community webinar with PPMD…Learn More